|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.360 |
Biomarker
|
disease |
BEFREE |
The aim of this study was the evaluation of copy number variations (CNVs) of hsa-miR-93, hsa-miR-122, hsa-miR-192 in CAD patients with or without T2DM.
|
31392905 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.360 |
Biomarker
|
disease |
BEFREE |
A total of 68 patients with type 2 DM and 11 healthy subjects were enrolled in a cross-sectional study and assessed concerning urinary albumin:creatinine ratio (UACR), urinary <i>N</i>-acetyl-β-D-glucosamininidase (NAG), urinary kidney injury molecule-1, urinary nephrin, podocalyxin, synaptopodin, estimated glomerular filtration rate (eGFR), urinary miRNA21, miRNA124, and miRNA192.
|
29279420 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
It was observed that there was higher miR‑377 expression and lower miR‑192 expression in T2D patients with and without DN compared with healthy controls (P<0.05). miR‑377 was higher in the normoalbuminuric group and gradually increased in the microalbuminuric and macroalbuminuric groups (P<0.05), whereas miR‑192 was lower in the macroalbuminuric group compared with the normoalbuminuric group (P<0.05).
|
29845236 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.360 |
Biomarker
|
disease |
BEFREE |
This miRNA is a 3' arm derived from the same pre-miRNA as miR-192 (miR-192-5p) implicated in type 2 diabetes, liver disease and cancers, and is predicted to target key genes in lipid metabolism.
|
26747651 |
2016 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.360 |
Biomarker
|
disease |
BEFREE |
CONCLUSIONS Genes including TAF1 and MAFK, and miRNAs including hsa-miR-29a, hsa-miR-192, and hsa-miR-144 might be potential target genes and important miRNAs for IFG and T2DM.
|
27906902 |
2016 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.360 |
Biomarker
|
disease |
BEFREE |
The clinical significance of five potential miRs (miR-21, miR-29a, miR-29b, miR-29c and miR192) in type 2 Diabetes Mellitus (T2DM) patients who have existing diabetic retinopathy with differential Albumin:Creatinine Ratio (ACR) and estimated Glomerular Filtration Rate (eGFR) was performed using quantitative RT-PCR analysis.
|
27279796 |
2016 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.360 |
Biomarker
|
disease |
CTD_human |
Cross-sectional studies disclosed a marked increase of miR-140-5p, miR-142-3p, and miR-222 and decreased miR-423-5p, miR-125b, miR-192, miR-195, miR-130b, miR-532-5p, and miR-126 in T2D patients.
|
24478399 |
2014 |
|
Hepatitis B
|
0.340 |
Biomarker
|
disease |
BEFREE |
Conclusions: Our findings indicate that miR-192-3p is a regulator of HBV infection and may play a potential role in hepatocellular carcinoma.
|
30180281 |
2019 |
|
Hepatitis B
|
0.340 |
Biomarker
|
disease |
BEFREE |
The three miRNAs mir-21, mir-122, mir-192, together with AFP, are biomarkers that may be applied to improve diagnostics of HCC in HBV patients, especially in HBV-related LC patients with normal AFP levels or HCC patients with small tumor sizes.
|
29672637 |
2018 |
|
Hepatitis B
|
0.340 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Hepatitis B
|
0.340 |
Biomarker
|
disease |
BEFREE |
In circulating vesicles, miRNA-192 (HBV: <i>p <</i> 0.0001; HCV: <i>p <</i> 0.0001), -200b (HBV: <i>p <</i> 0.0001; HCV: <i>p <</i> 0.0001), -92a (HBV: <i>p <</i> 0.0001; HCV: <i>p <</i> 0.0001), and -150 (HBV: <i>p</i> = 0.0016; HCV: <i>p</i> = 0.004) displayed a significant down-regulation in both HBV and HCV patients.
|
28232800 |
2017 |
|
Hepatitis B
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
These results indicated that persistent HBV infection might trigger NER impairment in part through upregulation of miR-192, which suppressed the levels of ERCC3 and ERCC4.
|
21672525 |
2011 |
|
Kidney Failure, Acute
|
0.320 |
Biomarker
|
disease |
CTD_human |
A scrutiny of circulating microRNA biomarkers for drug-induced tubular and glomerular injury in rats.
|
30682439 |
2019 |
|
Kidney Failure, Acute
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
Additionally, normalization of miRNA (miR-192-5p and miR-140-5p) implicated in AKI, poly(ADP-ribose) polymerase 1 levels, antiapoptotic signaling, intracellular NAD<sup>+</sup>, and mitochondrial oxidative phosphorylation were observed in the treatment group.
|
31532243 |
2019 |
|
Kidney Failure, Acute
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
Plasma miR-192 expression was induced in a time-dependent manner after IRI in rats and patients with AKI after cardiac surgery, comparably to the kidney injury development and recovery process, and may be useful for the detection of AKI.
|
28035621 |
2017 |
|
Kidney Diseases
|
0.310 |
Biomarker
|
group |
BEFREE |
MiR-192 is regarded as a potential noninvasive biomarker for kidney disease.
|
30808829 |
2019 |
|
Drug-Induced Liver Disease
|
0.310 |
Biomarker
|
phenotype |
BEFREE |
It has been demonstrated that miR-122 and miR-192, which are liver enriched, could be potential biomarkers of DILI; however, these miRNAs cannot discern types of injuries.
|
30125006 |
2018 |
|
Drug-Induced Liver Disease
|
0.310 |
Biomarker
|
phenotype |
CTD_human |
Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease.
|
28483554 |
2017 |
|
Drug-Induced Liver Disease
|
0.310 |
Biomarker
|
phenotype |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Drug-Induced Liver Disease
|
0.310 |
Biomarker
|
phenotype |
CTD_human |
Recently, circulating microRNAs (miRNAs) such as miR-122 and miR-192 have emerged as promising biomarkers of liver injury in preclinical species and in DILI patients.
|
25359176 |
2015 |
|
Kidney Diseases
|
0.310 |
Biomarker
|
group |
CTD_human |
Urinary microRNA profiling for identification of biomarkers after cisplatin-induced kidney injury.
|
24880025 |
2014 |
|
Drug-Induced Liver Disease
|
0.310 |
Biomarker
|
phenotype |
CTD_human |
Circulating microRNAs as potential markers of human drug-induced liver injury.
|
22045675 |
2011 |
|
Acute Kidney Insufficiency
|
0.300 |
Biomarker
|
disease |
CTD_human |
A scrutiny of circulating microRNA biomarkers for drug-induced tubular and glomerular injury in rats.
|
30682439 |
2019 |
|
Acute kidney injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
A scrutiny of circulating microRNA biomarkers for drug-induced tubular and glomerular injury in rats.
|
30682439 |
2019 |
|
Hepatitis, Toxic
|
0.300 |
Biomarker
|
disease |
CTD_human |
Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease.
|
28483554 |
2017 |